Titlebook: Gastrointestinal Stromal Tumor; Research and Practic Yukinori Kurokawa,Yoshito Komatsu Book 2019 Springer Nature Singapore Pte Ltd. 2019 Ga

原諒

忍耐

antidepressant

anagen

Coterminous

Surgery,ve the tumor without damaging the pseudocapsule. Removal of the lymph nodes is usually not necessary..Normally a laparoscopic excision is used on lesions under 5 cm. When using the magnification from a laparoscope, the blood vessels that are manipulated are held to a minimum and the nerves can be pr

Intercept

First-Line Treatment,current GIST, with a handful of patients surviving without progression for longer than 10?years. The most important predictive factor of the effect of imatinib is a c-kit gene mutation, with a gene mutation of EXON11 being a good prognostic factor. In addition to this, the factor related to the effe

天賦

Second- and Third-Line Treatment,has been identified as a potent inhibitor of VEGFR-1, VEGFR-2, fetal liver tyrosine kinase receptor 3 (FLT3), KIT (stem-cell factor [SCF] receptor), PDGFRα, and PDGFR. Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions

植物學(xué)

Adjuvant and Neoadjuvant Treatment,ressing high-risk features, such as large tumors or tumors with a high mitotic rate, are likely to develop recurrence with distant metastasis. In the past two decades, tyrosine kinase inhibitors were introduced for the treatment of GIST, and imatinib greatly prolonged the survival of metastatic or u

謊言

New Agents for Gastrointestinal Stromal Tumors,ecular targeted therapy (imatinib, sunitinib, and regorafenib). Developmental therapeutics for GIST is focused on primary or acquired resistance to these agents. In this section, we discuss new agents for the treatment of GIST.

neologism